NCT01593774View on ClinicalTrials.gov

Melatonin for Prevention of Metabolic Side Effects of Olanzapine

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Schizophrenia
Interventions
DRUG

Melatonin

Tablet melatonin 3 mg/day at 9 pm as intervention group

DRUG

Placebo

Placebo (with the same shape and taste as melatonin) at 9 pm as control group

Trial Locations (1)

55599-41939

Shafa Psychiatric Hospital, Rasht

All Listed Sponsors
lead

Guilan University of Medical Sciences

OTHER

NCT01593774 - Melatonin for Prevention of Metabolic Side Effects of Olanzapine | Biotech Hunter | Biotech Hunter